Laser study for HS scars pulled before it began
NCT ID NCT05470322
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test a fractional ablative erbium laser on scarring caused by hidradenitis suppurativa (HS) in the armpit area. It was designed for adults with mild HS activity and visible scars. However, the trial was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Er:YAG laser (fractional ablative laser)
- What this could lead to
- If it had worked, this laser treatment could have offered a way to improve the appearance of scars from hidradenitis suppurativa.
- What could go wrong
- The trial was withdrawn before any patients were treated, so we have no data on whether the laser is effective or safe for this use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy males and females, ≥ 18 years of age at time of informed consent with no upper age limit, seeking treatment for HS scarring in the axillary region. * Subjects must voluntarily sign and date an IRB approved informed consent form. * Subjects with diagnosis of HS (Hidradenitis Suppurativa) scarring recorded over the past 6 months. * Subject has an HS PGA (Hidradenitis Suppurativa Physician's Global Assessment) Scale of 0 or 1 * Able to read, understand and voluntarily provide written informed consent. * Subjects are determined to be healthy, non-smokers. * Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements. * Understand and accept the obligation not to undergo any other procedures in the areas to be treated through the follow-up period. Exclusion Criteria: * Subject does not have the capacity to consent to the study. * Subject underwent any medical-grade scar treatments (ie, lasers, excision procedures, topical prescriptions for scars) in the past 6 months prior to enrollment in the study. * Any history of keloid scarring. * Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months. * History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months. * Subject has no health contraindications to receiving local lidocaine and epinephrine injections, including but not limited to any form of heart disease or arrhythmia, untreated or uncontrolled severe hypertension, uncontrolled hyperthyroidism, uncontrolled diabetes, pheochromocytoma, Cocaine use. * History or current use of the following prescription medications:Accutane or other systemic retinoids within the past twelve months, Tricyclic antidepressant, monoamine oxidase inhibitors, B-blocker * Smoking or vaping in the past 12 months. * History of an allergy or an adverse reaction to hydroquinone or tretinoin. * History of photosensitivity and/or connective tissue disease. * History of uncontrolled diabetes, hypertension and depression. * History of ongoing pregnancy, active breastfeeding, cancer, and epilepsy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Einstein Advanced Care
Elmsford, New York, 10523, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Weight-Loss drug also calm a painful skin disease?
- Viruses that kill bacteria: a new weapon against superbugs?
- Can an injected drug calm the painful flares of hidradenitis suppurativa?
- Nanobody drug tested against painful skin condition
- Can a mediterranean diet tame hidradenitis suppurativa?
- Can we predict the path of chronic skin disease?